Voice disorder in patients with Parkinson’s disease. Parkinson's disease
Conditions
Interventions
Intervention 1: Intervention group: This group consists of 12 patients with Parkinson’s disease who receive routine drug treatment (Levodopa) and participate in 8 speech therapy sessions over 4 weeks
starting with 3 cm of water and gradually increasing by 1 cm in each session up to 9 cm. Includes silent blowing and producing the sound /u/ into the tube. 2. Finger kazoo with glissando: Creating mil
in three modes: steady, descending glissando, and ascending glissando. 3. Lip trill: Approximating the lips loosely and blowing air through them to create vibration and airflow. 4. Hand over mouth: Pl
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed by a neurologist with idiopathic Parkinson’s disease and hypokinetic dysarthria Under Levodopa medication: (Participants will receive a stable dose of Levodopa 30 days before the beginning of data collection and throughout the study process. The medication will not be discontinued during the study period. All assessment and treatment sessions will occur during the ‘on’ phase of the medication cycle, which usually begins about one hour after taking the medication and coincides with the peak of the drug’s effects.) A score of 1 or higher on the speech item in each section of the Unified Parkinson's Disease Rating Scale (UPDRS) for parts 2 and 3. A patient with hypophonia, who is experiencing speech and voice problems, has the ability to increase the loudness of their voice by about 5-10 dB at 30 cm SPL Has normal hearing and vision, with or without assistive devices Elementary school level literacy and reading ability for reading the text Absence of cognitive impairment (a score of 21 or higher on the Montreal Cognitive Assessment (MOCA) test) Not receiving a Parkinson 's-related speech/voice therapy program in the 2 years prior to study participation Absence of respiratory diseases, laryngeal injury, diagnosis and treatment of head and neck cancer, swallowing disorders, stroke, and other head injuries Not having early-onset Parkinson's (age less than 50 years) Not receiving complementary medical and surgical treatments, such as subthalamic nucleus deep brain stimulation
Exclusion criteria
Exclusion criteria: Affliction with atypical Parkinson's disease and other neurological changes concurrently with Parkinson's disease and/or psychiatric disorders, including depression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average voice loudness (intensity). Timepoint: First assessment session (before treatment begins) and final assessment after 8 treatment sessions (approximately 45 days after initial assessment). Method of measurement: Praat software. | — |
Secondary
| Measure | Time frame |
|---|---|
| Shimmer score. Timepoint: First assessment session (before treatment begins) and final assessment after 8 treatment sessions (approximately 45 days after initial assessment). Method of measurement: Praat software.;The score obtained on the Persian Voice Disability Coping Questionnaire (P-VDCQ). Timepoint: First assessment session (before treatment begins) and final assessment after 8 treatment sessions (approximately 45 days after initial assessment). Method of measurement: Voice Disability Coping Questionnaire.;Auditory-perceptual voice assessment. Timepoint: First assessment session (before treatment begins) and final assessment after 8 treatment sessions (approximately 45 days after initial assessment). Method of measurement: GRBAS perceptual analysis scale.;Aerodynamic evaluation (Maximum Phonation Time). Timepoint: First assessment session (before treatment begins) and final assessment after 8 treatment sessions (approximately 45 days after initial assessment). Method of measurement: Stopwatch.;Functional neural network activation patterns. Timepoint: First assessment session (before treatment begins) and final assessment after 8 treatment sessions (approximately 45 days after initial assessment). Method of measurement: Quantitative EEG or brain mapping. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShiva Ebrahimian
Shiraz University of Medical Sciences
Outcome results
None listed